Amgen
AMGN
$347.84
-0.77%
Amgen Inc. is a leading biotechnology company focused on discovering, developing, manufacturing, and delivering innovative human therapeutics, primarily in the areas of oncology, hematology, inflammation, bone health, cardiovascular disease, and rare diseases. The company is a long-established market leader in biotechnology, known for its deep pipeline, strong commercial portfolio including blockbuster drugs like Prolia and Otezla, and strategic acquisitions such as Horizon Therapeutics. The current investor narrative is dominated by the integration and performance of the Horizon acquisition, which brought key rare-disease assets like Tepezza, alongside navigating significant regulatory and safety concerns for drugs like Tavneos, as well as the broader industry impact of potential drug pricing tariffs.…
AMGN
Amgen
$347.84
Related headlines
Investment Opinion: Should I buy AMGN Today?
Hold. Amgen presents a balanced but complex risk/reward profile where its strong cash-generative business and growth trajectory are offset by a heavy debt load and notable regulatory overhangs, warranting a neutral stance pending clearer resolution of these risks.
The recommendation is supported by several key data points: 1) A reasonable forward P/E of 15.13x based on expected EPS growth, 2) Solid revenue growth of 8.91% YoY, 3) Exceptional profitability with a 20.99% net margin and $8.1B in TTM FCF, and 4) A low beta of 0.416 offering defensive characteristics. However, the stock trades at a premium trailing P/E of 22.84x and carries a debt-to-equity ratio of 6.31, which is high relative to financial health benchmarks.
The thesis would upgrade to a Buy if debt is reduced meaningfully (D/E trending below 5.0), quarterly earnings volatility subsides, and the Tavneos safety concerns are resolved without material commercial impact. It would downgrade to a Sell if revenue growth decelerates below 5%, FCF weakens substantially impairing debt service, or a new major safety/regulatory issue emerges. Relative to its own historical P/E range (11.36x to 56x) and its growth profile, the stock appears fairly valued at current levels, neither offering a clear margin of safety nor being egregiously overpriced.
Sign up to view all
AMGN 12-Month Price Forecast
Amgen is a 'show me' story for the next 12 months. The potential is clear: a forward earnings discount, strong cash flow, and a diversified portfolio. However, the elevated debt and specific drug safety risks create a tangible ceiling on valuation and investor enthusiasm. The base case of steady execution is most probable, leading to range-bound trading. The stance would upgrade to bullish on evidence of sustained debt reduction and resolution of the Tavneos overhang. It would turn bearish if quarterly earnings volatility increases or free cash flow generation meaningfully deteriorates.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Amgen's 12-month outlook, with a consensus price target around $452.19 and implied upside of +30.0% versus the current price.
Average Target
$452.19
13 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
13
covering this stock
Price Range
$278 - $452
Analyst target range
Amgen is covered by 13 analysts, indicating substantial institutional interest. The consensus sentiment leans neutral to slightly bullish, as evidenced by recent institutional ratings which include actions like 'Overweight', 'Buy', and 'Equal Weight' or 'Neutral'. The average target price is not explicitly provided in the data, so the implied upside/downside cannot be calculated; however, the distribution of recent actions shows a mix of positive and neutral stances. The target price range is also not specified in the provided dataset. The high target would likely assume successful integration of Horizon's assets, robust growth from newer products like Tezspire and Lumakras, and manageable regulatory headwinds. The low target would factor in risks such as the safety concerns around Tavneos, pricing pressure, and the high debt burden. The recent pattern of analyst actions shows no major downgrades in early 2026, with most firms reiterating their ratings, suggesting a period of watchful waiting as the company executes its post-acquisition strategy.
Bulls vs Bears: AMGN Investment Factors
The investment debate for Amgen centers on a clash between its strong fundamental growth engine and its elevated financial and operational risks. The bull case is supported by compelling forward earnings growth expectations, robust revenue expansion, exceptional cash generation, and a defensive low-beta profile. The bear case hinges on an unsustainable debt load, acute regulatory safety risks for key drugs, and volatile earnings. Currently, the bull side has stronger evidence due to the concrete data showing 8.9% revenue growth, a forward P/E discount, and $8.1B in annual FCF to manage debt. The single most important tension is the resolution of the Horizon acquisition's integration: successful execution and debt paydown would validate the bull thesis, while any misstep combined with a Tavneos safety setback could trigger a severe derating of the stock.
Bullish
- Strong Forward Earnings Growth: The forward P/E of 15.13x is a 34% discount to the trailing P/E of 22.84x, implying the market expects significant earnings growth. This is supported by analyst consensus expecting forward EPS of $27.48, representing substantial growth from recent quarterly results. The PEG ratio of 0.26 suggests the stock is undervalued relative to its expected earnings growth rate.
- Robust Revenue Growth and Portfolio: Q4 2025 revenue grew 8.91% YoY to $9.90 billion, demonstrating positive momentum. The sequential quarterly growth from Q1 to Q4 2025 shows a strengthening commercial portfolio, driven by key products like Prolia ($1.05B), Otezla ($625M), and new launches Tezspire ($474M) and Tepezza ($457M). This diversified growth reduces reliance on any single blockbuster.
- Exceptional Profitability and Cash Flow: The company maintains a high gross margin of 81.91% (Q4 2025) and a trailing net margin of 20.99%. It generates massive free cash flow, with TTM FCF of $8.1 billion, providing ample liquidity to service its debt, fund R&D, and return capital to shareholders. This financial strength underpins the 2.9% dividend yield.
- Defensive Low-Beta Profile: With a beta of 0.416, AMGN is significantly less volatile than the broader market. This defensive characteristic, combined with its 1-year price gain of 19.48%, offers a favorable risk-adjusted return profile, making it attractive for risk-averse investors seeking stability in healthcare.
Bearish
- Extremely High Debt Burden: The debt-to-equity ratio of 6.31 is alarmingly high, reflecting the significant leverage taken on to finance the Horizon Therapeutics acquisition. This constrains financial flexibility and increases interest expense risk, with Q4 2025 interest expense at $653 million, consuming a substantial portion of operating income.
- Significant Regulatory and Safety Risks: Recent news highlights severe safety concerns for Tavneos, including an FDA warning about fatal liver risks. This introduces material commercial, reputational, and potential litigation risks that could impair sales and lead to costly label restrictions or withdrawals, directly impacting future revenue streams.
- Earnings and Margin Volatility: Quarterly profitability is highly volatile, as seen in the jump from Q3 2025 net income of $3.22B (33.7% margin) to Q4's $1.33B (13.5% margin). Gross margin also fluctuated from 67.75% in Q3 to 81.91% in Q4, indicating inconsistent cost management and earnings quality that complicates forecasting.
- Valuation Premium and Technical Weakness: The trailing P/E of 22.84x trades at a premium to many large-cap pharma peers. Technically, the stock is in a corrective phase, down 3.01% over 3 months and facing resistance near its 52-week high of $391.29. Its current price of $355.20 is 16.5% below that high, suggesting weakened momentum.
AMGN Technical Analysis
Amgen's stock is in a sustained uptrend over the past year, evidenced by a 1-year price change of +19.48%, but it is currently trading in a corrective phase from recent highs. The current price of $355.20 sits approximately 73% of the way up from its 52-week low of $267.83 towards its high of $391.29, indicating it is in the upper-mid range of its annual band, having retreated from peak momentum. Recent momentum shows a short-term recovery, with a 1-month gain of +5.57%, which contrasts with a 3-month decline of -3.01%, suggesting the stock is attempting to stabilize after a pullback from its February highs near $388. This divergence indicates a potential consolidation phase as the stock digests its earlier gains, with the positive 1-month move signaling a tentative rebound. Key technical support is anchored at the 52-week low of $267.83, while immediate overhead resistance is at the 52-week high of $391.29; a decisive breakout above this level would signal a resumption of the primary uptrend, while a breakdown below recent lows near $320 could indicate a deeper correction. The stock's beta of 0.416 indicates it is significantly less volatile than the broader market (SPY), which is typical for a large-cap biopharma and suggests it may offer defensive characteristics during market turbulence.
Beta
0.42
0.42x market volatility
Max Drawdown
-16.6%
Largest decline past year
52-Week Range
$268-$391
Price range past year
Annual Return
+17.7%
Cumulative gain past year
| Period | AMGN Return | S&P 500 |
|---|---|---|
| 1m | +6.6% | +1.5% |
| 3m | -1.0% | +13.4% |
| 6m | +7.2% | +10.9% |
| 1y | +17.7% | +24.5% |
| ytd | +6.2% | +10.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
AMGN Fundamental Analysis
Amgen's revenue trajectory is showing steady growth, with Q4 2025 revenue of $9.896 billion representing a solid 8.91% year-over-year increase. The multi-quarter trend from Q1 2025 ($8.149B) to Q4 2025 ($9.896B) demonstrates sequential quarterly growth, indicating a positive momentum driven by its broad portfolio, including contributions from the Horizon acquisition. Segment data highlights key growth drivers like Prolia ($1.054B), Otezla ($625M), and newer launches such as TEZSPIRE ($474M) and TEPEZZA ($457M). The company is solidly profitable, with Q4 2025 net income of $1.333 billion and a robust gross margin of 81.91%. Profitability has been somewhat volatile quarter-to-quarter, as seen in the jump from Q3 2025 net income of $3.216 billion (gross margin 67.75%) to the Q4 figure, but the trailing twelve-month net margin of 20.99% indicates overall healthy earnings power. The balance sheet carries significant leverage, with a debt-to-equity ratio of 6.31, reflecting the financing used for the Horizon acquisition. However, financial health is supported by strong cash generation, with free cash flow (TTM) of $8.1 billion and a current ratio of 1.14, providing adequate liquidity to service debt and fund operations, though the high debt load remains a key focus for investors.
Quarterly Revenue
$9.9B
2025-12
Revenue YoY Growth
+0.08%
YoY Comparison
Gross Margin
+0.81%
Latest Quarter
Free Cash Flow
$8.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is AMGN Overvalued?
Given Amgen's positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE ratio is 22.84x, while the forward PE is notably lower at 15.13x. This significant gap implies the market expects substantial earnings growth, likely from the full integration of Horizon and pipeline contributions, which is priced into the forward multiple. Compared to sector averages, Amgen's trailing PE of 22.84x trades at a premium; for context, the provided valuation data shows an EV/EBITDA of 13.11x and a Price/Sales of 4.79x, which would need to be compared against industry medians for a full peer assessment, but the forward PE discount suggests the market sees value relative to future earnings. Historically, the stock's own PE ratio has fluctuated widely, as seen in the historical data ranging from 11.36x in Q1 2023 to over 56x in late 2024. The current trailing PE of 22.84x sits near the middle of this expansive historical range, suggesting the valuation is not at an extreme and reflects a balanced view of the company's growth prospects against its integration and regulatory risks.
PE
22.8x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -336x~75x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.1x
Enterprise Value Multiple
Investment Risk Disclosure
Amgen's primary financial risk is its extreme leverage, with a debt-to-equity ratio of 6.31, one of the highest in the sector. This debt, used to fund the Horizon acquisition, results in substantial interest expense, which was $653 million in Q4 2025 alone. While strong free cash flow of $8.1 billion provides a cushion, a significant earnings downturn could pressure its ability to service debt comfortably. Operationally, earnings volatility is a concern, with net income swinging from $3.22 billion to $1.33 billion between consecutive quarters, indicating potential integration challenges or one-time charges that complicate the investment narrative.
Market risks include trading at a premium valuation, with a trailing P/E of 22.84x above many mature pharma peers, creating compression risk if growth disappoints. The competitive landscape is intensifying, as highlighted by news focusing on Eli Lilly and Novo Nordisk in weight loss, areas where Amgen is not a leader. Furthermore, the stock exhibits significant sector-specific regulatory risk, exemplified by the FDA's fatal liver warning for Tavneos and the looming threat of punitive drug tariffs, which could disrupt pricing power and margin assumptions across the portfolio.
The worst-case scenario involves a confluence of events: a major safety-related withdrawal or severe restriction of Tavneos, leading to lost revenue and litigation; a failure to achieve the earnings growth implied by the forward P/E multiple, triggering multiple compression; and rising interest rates increasing the cost of its massive debt burden. This could realistically drive the stock back to its 52-week low of $267.83, representing a potential downside of -24.6% from the current price of $355.20. The historical max drawdown of -16.57% suggests the stock can experience sharp corrections, and a bear market in healthcare could exacerbate these company-specific issues.
FAQ
The key risks are, in order of severity: 1) Financial Risk: An extremely high debt-to-equity ratio of 6.31, which could limit strategic flexibility and amplify losses in a downturn. 2) Regulatory/Safety Risk: Acute concerns for Tavneos, including an FDA warning of fatal liver risks, which could lead to sales collapse and litigation. 3) Execution Risk: Volatile quarterly earnings (net income swung from $3.22B to $1.33B) indicate potential integration challenges post-Horizon acquisition. 4) Macro/Political Risk: Exposure to potential drug pricing tariffs and ongoing political scrutiny of pharmaceutical pricing.
The 12-month forecast presents three scenarios. The Base Case (55% probability) sees the stock trading between $340 and $380, as the company executes steadily on its growth plan while managing its debt. The Bull Case (30% probability) targets $391 to $420 on successful integration and debt paydown. The Bear Case (15% probability) warns of a drop to $268-$320 if Tavneos safety issues escalate or earnings disappoint. The most likely outcome is the Base Case, predicated on the assumption that Amgen's strong free cash flow will allow it to gradually de-lever while maintaining low-single-digit revenue growth.
AMGN appears fairly valued. Its trailing P/E of 22.84x is at a premium to many large-cap pharma peers, reflecting its biotech growth profile. However, its forward P/E of 15.13x represents a significant discount, implying the market is pricing in substantial earnings growth. Key valuation metrics like the PEG ratio of 0.26 scream undervaluation, but this is offset by the high Price/Book of 20.34x due to massive debt. The valuation implies the market expects successful Horizon integration and debt management to unlock the embedded earnings growth, but is withholding a premium multiple until these are demonstrated.
AMGN is a Hold, not a clear-cut buy at current levels. For income-oriented or defensive investors, its 2.9% dividend yield and low beta (0.416) are attractive features. The forward P/E of 15.13x suggests reasonable value if the company delivers on its earnings growth forecast. However, the high debt load (D/E of 6.31) and specific regulatory risks around Tavneos introduce significant uncertainty. It could be a good buy for patient, long-term investors on a pullback closer to $340, where the risk/reward improves, but it requires a high tolerance for balance sheet and regulatory headline risk.
AMGN is far more suitable for a long-term investment horizon (3-5 years minimum). Its low beta and dividend make it a poor candidate for short-term trading, as it typically won't match the volatility of high-growth tech stocks. The investment thesis hinges on the multi-year process of integrating Horizon, paying down debt, and advancing the pipeline—outcomes that won't be resolved in quarters. The stock's defensive characteristics also align with a long-term, buy-and-hold strategy within a diversified portfolio. Short-term traders would be better served by more volatile biotech names with binary catalysts.